Related Experiment Video
Updated: Sep 20, 2026

Plaque Assay for Murine Norovirus
Published on: August 22, 2012
Inhibition of murine plaque-forming cell responses in vivo by ribavirin
Abstract:
The effects of ribavirin, a potent inhibitor of RNA and DNA virus replication, on the generation of primary plaque-forming cell (PFC) responses in vivo has been investigated. Intraperitoneal administration of ribavirin 1 day after immunization of C3H/HeJ mice with sheep erythrocytes (SRBC) suppressed splenic IgM and IgG PFC responses by 60 to 90%. Primary IgM PFC responses of C3HeB/FeJ mice to bacterial lipopolysaccharides (LPS), a T-independent antigen, were also inhibited to a similar extent. Inhibition of splenic PFC responses, without significant reduction in nucleated cell recoveries, was dose dependent between 0.5 and 4 mg ribavirin. Varying the time of treatment determined that optimal inhibitory activity occurred when ribavirin was administered simultaneously or 1 day after antigen. Kinetic analysis of PFC responses in ribavirin-treated mice revealed that suppression did not result from a delay in development since reduced numbers of PFC were found at all times after immunization. Ribavirin-treatment after primary sensitization in vivo also impaired the capacity of spleen cells to develop secondary PFC responses in vitro, indicating that ribavirin also inhibited memory cell generation.
Insights
Ribavirin, an antiviral drug, significantly suppresses immune responses in mice. This study shows ribavirin inhibits both T-dependent and T-independent plaque-forming cell (PFC) generation and memory cell development.
Area of Science:
- Immunology
- Virology
- Pharmacology
Background:
- Ribavirin is a broad-spectrum antiviral agent known to inhibit viral RNA and DNA replication.
- The impact of ribavirin on the host immune system, particularly cellular immune responses, requires further elucidation.
Purpose of the Study:
- To investigate the effects of ribavirin on the generation of primary plaque-forming cell (PFC) responses in vivo.
- To determine ribavirin's influence on both T-dependent and T-independent immune responses.
- To assess ribavirin's impact on the development of immunological memory.
Main Methods:
- Mice (C3H/HeJ and C3HeB/FeJ) were immunized with sheep erythrocytes (SRBC) or bacterial lipopolysaccharides (LPS).
- Ribavirin was administered intraperitoneally at varying doses and time points relative to antigen exposure.
- Splenic IgM and IgG PFC responses were quantified.
- Nucleated cell counts were assessed.
- In vitro secondary PFC responses were evaluated using spleen cells from treated mice.
Main Results:
- Ribavirin administration suppressed splenic IgM and IgG PFC responses to SRBC by 60-90%.
- Similar inhibition was observed for T-independent IgM PFC responses to LPS.
- The observed inhibition was dose-dependent, occurring between 0.5 and 4 mg of ribavirin.
- Optimal suppression was achieved when ribavirin was given concurrently with or one day after antigen.
- Suppression was not due to delayed kinetics but a reduction in PFC numbers at all time points.
- Ribavirin treatment impaired the generation of memory B cells, as evidenced by reduced in vitro secondary PFC responses.
Conclusions:
- Ribavirin significantly inhibits primary B cell responses, affecting both T-dependent and T-independent antigens.
- The drug's immunomodulatory effects extend to the inhibition of memory cell generation.
- These findings highlight the potential for ribavirin to impact host immune functions beyond its antiviral activity.
Related Concept Videos
Respiratory Syncytial Virus Disease
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly

